Literature DB >> 32516090

Reply to S. Takamizawa et al.

Nadine Tung1, Michele R Hacker1, Judy E Garber1.   

Abstract

Mesh:

Substances:

Year:  2020        PMID: 32516090      PMCID: PMC7402997          DOI: 10.1200/JCO.20.01190

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  8 in total

1.  Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).

Authors:  Nasim Mavaddat; Daniel Barrowdale; Irene L Andrulis; Susan M Domchek; Diana Eccles; Heli Nevanlinna; Susan J Ramus; Amanda Spurdle; Mark Robson; Mark Sherman; Anna Marie Mulligan; Fergus J Couch; Christoph Engel; Lesley McGuffog; Sue Healey; Olga M Sinilnikova; Melissa C Southey; Mary Beth Terry; David Goldgar; Frances O'Malley; Esther M John; Ramunas Janavicius; Laima Tihomirova; Thomas V O Hansen; Finn C Nielsen; Ana Osorio; Alexandra Stavropoulou; Javier Benítez; Siranoush Manoukian; Bernard Peissel; Monica Barile; Sara Volorio; Barbara Pasini; Riccardo Dolcetti; Anna Laura Putignano; Laura Ottini; Paolo Radice; Ute Hamann; Muhammad U Rashid; Frans B Hogervorst; Mieke Kriege; Rob B van der Luijt; Susan Peock; Debra Frost; D Gareth Evans; Carole Brewer; Lisa Walker; Mark T Rogers; Lucy E Side; Catherine Houghton; JoEllen Weaver; Andrew K Godwin; Rita K Schmutzler; Barbara Wappenschmidt; Alfons Meindl; Karin Kast; Norbert Arnold; Dieter Niederacher; Christian Sutter; Helmut Deissler; Doroteha Gadzicki; Sabine Preisler-Adams; Raymonda Varon-Mateeva; Ines Schönbuchner; Heidrun Gevensleben; Dominique Stoppa-Lyonnet; Muriel Belotti; Laure Barjhoux; Claudine Isaacs; Beth N Peshkin; Trinidad Caldes; Miguel de la Hoya; Carmen Cañadas; Tuomas Heikkinen; Päivi Heikkilä; Kristiina Aittomäki; Ignacio Blanco; Conxi Lazaro; Joan Brunet; Bjarni A Agnarsson; Adalgeir Arason; Rosa B Barkardottir; Martine Dumont; Jacques Simard; Marco Montagna; Simona Agata; Emma D'Andrea; Max Yan; Stephen Fox; Timothy R Rebbeck; Wendy Rubinstein; Nadine Tung; Judy E Garber; Xianshu Wang; Zachary Fredericksen; Vernon S Pankratz; Noralane M Lindor; Csilla Szabo; Kenneth Offit; Rita Sakr; Mia M Gaudet; Christian F Singer; Muy-Kheng Tea; Christine Rappaport; Phuong L Mai; Mark H Greene; Anna Sokolenko; Evgeny Imyanitov; Amanda Ewart Toland; Leigha Senter; Kevin Sweet; Mads Thomassen; Anne-Marie Gerdes; Torben Kruse; Maria Caligo; Paolo Aretini; Johanna Rantala; Anna von Wachenfeld; Karin Henriksson; Linda Steele; Susan L Neuhausen; Robert Nussbaum; Mary Beattie; Kunle Odunsi; Lara Sucheston; Simon A Gayther; Kate Nathanson; Jenny Gross; Christine Walsh; Beth Karlan; Georgia Chenevix-Trench; Douglas F Easton; Antonis C Antoniou
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-12-05       Impact factor: 4.254

2.  TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.

Authors:  Steven J Isakoff; Erica L Mayer; Lei He; Tiffany A Traina; Lisa A Carey; Karen J Krag; Hope S Rugo; Minetta C Liu; Vered Stearns; Steven E Come; Kirsten M Timms; Anne-Renee Hartman; Darrel R Borger; Dianne M Finkelstein; Judy E Garber; Paula D Ryan; Eric P Winer; Paul E Goss; Leif W Ellisen
Journal:  J Clin Oncol       Date:  2015-04-06       Impact factor: 44.544

3.  Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients.

Authors:  T Byrski; T Huzarski; R Dent; E Marczyk; M Jasiowka; J Gronwald; J Jakubowicz; C Cybulski; R Wisniowski; D Godlewski; J Lubinski; S A Narod
Journal:  Breast Cancer Res Treat       Date:  2014-08-17       Impact factor: 4.872

4.  Neoadjuvant Cisplatin in BRCA Carriers With HER2-Negative Breast Cancer.

Authors:  Shigemasa Takamizawa; Hiroto Ishiki; Tatsunori Shimoi; Masaki Shimizu; Eriko Satomi
Journal:  J Clin Oncol       Date:  2020-06-09       Impact factor: 44.544

5.  Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.

Authors:  Tomasz Byrski; Jacek Gronwald; Tomasz Huzarski; Ewa Grzybowska; Magdalena Budryk; Malgorzata Stawicka; Tomasz Mierzwa; Marek Szwiec; Rafal Wisniowski; Monika Siolek; Rebecca Dent; Jan Lubinski; Steven Narod
Journal:  J Clin Oncol       Date:  2009-12-14       Impact factor: 44.544

6.  TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline BRCA Carriers With HER2-Negative Breast Cancer (the INFORM trial).

Authors:  Nadine Tung; Banu Arun; Michele R Hacker; Erin Hofstatter; Deborah L Toppmeyer; Steven J Isakoff; Virginia Borges; Robert D Legare; Claudine Isaacs; Antonio C Wolff; Paul Kelly Marcom; Erica L Mayer; Paulina B Lange; Andrew J Goss; Colby Jenkins; Ian E Krop; Eric P Winer; Stuart J Schnitt; Judy E Garber
Journal:  J Clin Oncol       Date:  2020-02-25       Impact factor: 44.544

7.  Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial.

Authors:  Andrew Tutt; Holly Tovey; Maggie Chon U Cheang; Sarah Kernaghan; Lucy Kilburn; Patrycja Gazinska; Julie Owen; Jacinta Abraham; Sophie Barrett; Peter Barrett-Lee; Robert Brown; Stephen Chan; Mitchell Dowsett; James M Flanagan; Lisa Fox; Anita Grigoriadis; Alexander Gutin; Catherine Harper-Wynne; Matthew Q Hatton; Katherine A Hoadley; Jyoti Parikh; Peter Parker; Charles M Perou; Rebecca Roylance; Vandna Shah; Adam Shaw; Ian E Smith; Kirsten M Timms; Andrew M Wardley; Gregory Wilson; Cheryl Gillett; Jerry S Lanchbury; Alan Ashworth; Nazneen Rahman; Mark Harries; Paul Ellis; Sarah E Pinder; Judith M Bliss
Journal:  Nat Med       Date:  2018-04-30       Impact factor: 53.440

Review 8.  The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis.

Authors:  Olga Caramelo; Cristina Silva; Francisco Caramelo; Cristina Frutuoso; Teresa Almeida-Santos
Journal:  Hered Cancer Clin Pract       Date:  2019-03-25       Impact factor: 2.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.